生理抗凝剂的替代功能
Teagan Prouse1, Alan E Mast2, Vera Ignjatovic3
1Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States.
Journal of thrombosis and haemostasis : JTH
|September 4, 2025
概括
除了血液凝固之外,抗血栓素 (AT) 和蛋白C (PC) 等生理抗血栓剂有不同的作用. 最近的研究揭示了它们在治疗癌症和中风等疾病方面的潜力.
科学领域:
- 生理学
- 血液学
- 药理学
背景情况:
- 抗凝蛋白,包括抗血 (AT),蛋白C (PC),蛋白S (PS) 和组织因子通路抑制剂 (TFPI),是血液静止的关键调节剂.
- 这些蛋白质具有抗凝活动,并发挥其他生理功能,影响各种疾病,而不仅仅是血栓和出血.
- 了解这些多方面的作用是开发新疗法的关键.
研究的目的:
- 审查最近 (2018-2025) 关于AT,PC,PS和TFPI在临床疾病中的替代生理功能的文献.
- 探索这些抗凝剂在各种医学领域的治疗应用.
- 根据这些蛋白质的非血静作用突出显示新兴的治疗途径.
主要方法:
- 在PubMed的综合文献搜索中,查找2018年至2025年初发表的文章.
- 针对不同临床疾病类别的AT,PC,PS和TFPI的替代功能进行研究.
- 选择治疗应用的分类,包括癌症,心血管疾病,孕妇健康,炎症,感染,中风等.
主要成果:
- 除了抗凝血功能之外,还发现了AT,PC,PS和TFPI的重要影响.
- 记录了瘤学,心血管医学,神经学和传染病中的新兴治疗应用.
- 突出了与内皮细胞和血小板的新相互作用,以及在血脑屏障保护中的作用.
结论:
- AT,PC,PS 和 TFPI 的不同生理作用为广泛的人类疾病提供了有前途的治疗潜力.
- 进一步研究这些替代功能可以开启新的治疗策略.
- 这些发现强调了考虑非血栓性疾病的抗凝剂的重要性.
更多相关视频
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
888
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
888
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
642
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
642
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Extrinsic and Intrinsic Pathways of Hemostasis
9.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.1K


